Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Glucagon-like peptide-1 receptor agonists may benefit cardiopulmonary outcomes in patients with COPD
Thorax ( IF 9.0 ) Pub Date : 2024-11-01 , DOI: 10.1136/thorax-2023-221040 Fu-Shun Yen, Chih-Cheng Hsu, James Cheng-Chung Wei, Fuu-Jen Tsai, Yuhan Huang, Teng-Shun Yu, Chii-Min Hwu
Thorax ( IF 9.0 ) Pub Date : 2024-11-01 , DOI: 10.1136/thorax-2023-221040 Fu-Shun Yen, Chih-Cheng Hsu, James Cheng-Chung Wei, Fuu-Jen Tsai, Yuhan Huang, Teng-Shun Yu, Chii-Min Hwu
Background Clinical studies have shown that glucagon-like peptide-1 receptor agonists (GLP-1 RA) can have beneficial effects on cardiopulmonary function. We conducted this longitudinal cohort study to compare the risk of cardiopulmonary outcomes and mortality between GLP-1 RA use and no use in patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disease (COPD). Methods The study identified 8060 matched GLP-1 RA users and non-users from Taiwan’s National Health Insurance Research Database from 1 January 2008 to 31 December 2019. Cox proportional hazards models were used to determine the risk of cardiopulmonary outcomes between GLP-1 RA users and non-users. Results The mean follow-up time was 2.51 and 2.46 years for GLP-1 RA users and non-users, respectively. In the matched cohorts, GLP-1 RA users had a significantly lower risk of mortality (adjusted HR (aHR) 0.46, 95% CI 0.38 to 0.56), cardiovascular events (aHR 0.73, 95% CI 0.65 to 0.82), non-invasive positive pressure ventilation (aHR 0.66, 95% CI 0.47 to 0.93), invasive mechanical ventilation (aHR 0.64, 95% CI 0.51 to 0.8) and bacterial pneumonia (aHR 0.76, 95% CI 0.65 to 0.88) than GLP-1 RA non-users. The subsequent analyses for various subgroup and medication duration also showed that GLP-1 RA was associated with a significantly lower risk of mortality, cardiovascular events, ventilation support and bacterial pneumonia than non-GLP-1 RA. Conclusion This nationwide cohort study showed that GLP-1 RA had a lower risk of cardiopulmonary outcomes and all-cause mortality than non-GLP-1 RA in patients with T2D and COPD. GLP-1 RA may help manage diabetes in people with COPD. No data are available. Data of this study are available from the National Health Insurance Research Database (NHIRD) published by Taiwan National Health Insurance (NHI) Administration. The data used in this study cannot be made available in the paper, the supplemental files or in a public repository due to the ‘Personal Information Protection Act’ executed by Taiwan government starting from 2012. Requests for data can be sent as a formal proposal to the NHIRD office () or by email to stsung@mohw.gov.tw.
更新日期：2024-10-16
京公网安备 11010802027423号